Amneal Pharmaceuticals (NASDAQ:AMRX) Rating Increased to Strong-Buy at StockNews.com

Amneal Pharmaceuticals (NASDAQ:AMRX) was upgraded by research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a research report issued on Monday.

AMRX has been the topic of several other reports. Barclays increased their price objective on shares of Amneal Pharmaceuticals from $8.00 to $10.00 and gave the company an “overweight” rating in a report on Tuesday, August 13th. Piper Sandler raised their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research report on Monday. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price objective for the company in a report on Friday, September 6th. Finally, Truist Financial raised their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Amneal Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $10.00.

Amneal Pharmaceuticals Trading Up 0.5 %

Amneal Pharmaceuticals stock opened at $9.25 on Monday. The company has a market cap of $2.86 billion, a PE ratio of -13.53 and a beta of 1.17. Amneal Pharmaceuticals has a 1 year low of $4.15 and a 1 year high of $9.48. The company’s 50-day moving average is $8.54 and its two-hundred day moving average is $7.59.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hennessy Advisors Inc. bought a new stake in shares of Amneal Pharmaceuticals in the second quarter worth about $8,818,000. Rubric Capital Management LP raised its holdings in Amneal Pharmaceuticals by 12.4% during the 2nd quarter. Rubric Capital Management LP now owns 10,721,778 shares of the company’s stock worth $68,083,000 after buying an additional 1,179,830 shares during the period. Acadian Asset Management LLC lifted its stake in Amneal Pharmaceuticals by 701.8% in the second quarter. Acadian Asset Management LLC now owns 811,853 shares of the company’s stock valued at $5,148,000 after buying an additional 710,598 shares in the last quarter. Assenagon Asset Management S.A. boosted its holdings in shares of Amneal Pharmaceuticals by 114.1% in the third quarter. Assenagon Asset Management S.A. now owns 1,204,994 shares of the company’s stock valued at $10,026,000 after buying an additional 642,065 shares during the period. Finally, Dimensional Fund Advisors LP increased its position in shares of Amneal Pharmaceuticals by 17.6% during the second quarter. Dimensional Fund Advisors LP now owns 4,283,928 shares of the company’s stock worth $27,205,000 after acquiring an additional 641,405 shares in the last quarter. 31.82% of the stock is currently owned by institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.